the MCCE vs EGD Trial

Launched by CHINESE UNIVERSITY OF HONG KONG · May 27, 2025

Keywords

ClinConnect Summary

The MCCE vs EGD Trial is studying how well a new, less invasive test called Magnetically Controlled Capsule Endoscopy (MCCE) can help find the cause of anaemia in patients who have acute coronary syndrome (ACS). ACS is a serious heart condition that can cause chest pain and shortness of breath. Traditionally, doctors use a procedure called Esophageal-gastro-Duodenoscopy (EGD) to look for reasons behind anaemia, but this method often doesn’t provide clear answers. The trial aims to see if MCCE can be a better option for these patients.

To participate in this trial, individuals must be over 18 years old and diagnosed with ACS alongside new anaemia, which means their hemoglobin levels are below 11 g/dL when they are admitted to the hospital. However, there are certain conditions that would exclude someone from participating, such as having certain blood disorders, active cancer, or specific gastrointestinal issues. If eligible, participants can expect to undergo the MCCE test, which is less invasive than EGD and may help doctors better understand their anaemia without the same risks associated with traditional methods. This trial is currently not recruiting participants yet, but it represents a step towards improving diagnostic options for patients with these health challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• subjects are patients older than 18 years old with:
• • 1. the diagnosis of ACS as defined by symptoms of chest pain or shortness-of-breath, abnormal electrocardiogram and positive enzyme, requiring coronary intervention
• • 2. new-onset anaemia as defined by Hb\<11 g/dL on admission blood taking
• Exclusion Criteria:
• • 1. History of active haematological disease including hemoglobinopathies such as thalassemia, Myelodysplastic syndromes, haematological malignancy, aplastic anaemia, or autoimmune haemolytic anaemia.
• • 2. Patients with known active gastrointestinal malignancy.
• • 3. Contraindications for CE: suspected or known gastrointestinal obstruction, stenosis, fistula, diverticula, presence of gastrointestinal obstruction symptoms such as pain or dysphagia; inoperative conditions or refusal to undergo abdominal surgery if required; history of laparotomy, gastric or bowel surgery; presence of metallic implants that is not MRI conditional.
• • 4. Contraindications for EGD: Possible gastrointestinal perforation, medically unstable patients, patient with known pharyngeal diverticulum, and patients with recent head and neck trauma.
• • 5. Inability to take 1-month DAPT such as non-deferrable surgery within 1 months, severe allergy or hypersensitivity reaction to aspirin or P2Y12 inhibitors, or patients in whom 1 months DAPT is not indicated.
• • 6. Patients whose life-expectancy is less than 6 months.
• • 7. Patients who are pregnant or lactating.
• • 8. Patients who are unable to give informed consent.
• • 9. Patients who are in active heart failure or fluid-overload state.
• • 10. Patients who have chronic renal failure as defined by estimated glomerular filtration rate \<15 ml/min/1.73m2.